78 related articles for article (PubMed ID: 3180142)
21. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.
Pietras RJ; Pegram MD; Finn RS; Maneval DA; Slamon DJ
Oncogene; 1998 Oct; 17(17):2235-49. PubMed ID: 9811454
[TBL] [Abstract][Full Text] [Related]
22. Vascular endothelial growth factor immunoneutralization in combination with cisplatin reduces EAC tumor growth.
Ghosh S; Maity P
Int Immunopharmacol; 2006 Oct; 6(10):1550-9. PubMed ID: 16919827
[TBL] [Abstract][Full Text] [Related]
23. Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors.
Thaker PH; Yazici S; Nilsson MB; Yokoi K; Tsan RZ; He J; Kim SJ; Fidler IJ; Sood AK
Clin Cancer Res; 2005 Jul; 11(13):4923-33. PubMed ID: 16000591
[TBL] [Abstract][Full Text] [Related]
24. Gene therapy of adenovirus mediated CD ::upp/5-FC directed by GSTP1 promoter in cisplatin-resistant ovarian cancer.
Wang Z; Cai L; Wang H
Gynecol Oncol; 2005 Mar; 96(3):643-50. PubMed ID: 15721406
[TBL] [Abstract][Full Text] [Related]
25. [Combination chemotherapy of paclitaxel followed by nedaplatin for human ovarian cancer].
Uchida N; Yamada H; Maekawa R; Yoshioka T
Gan To Kagaku Ryoho; 2002 Nov; 29(11):1943-9. PubMed ID: 12465394
[TBL] [Abstract][Full Text] [Related]
26. Synthetic retinoid fenretinide is effective against a human ovarian carcinoma xenograft and potentiates cisplatin activity.
Formelli F; Cleris L
Cancer Res; 1993 Nov; 53(22):5374-6. PubMed ID: 8221674
[TBL] [Abstract][Full Text] [Related]
27. [Telomerase antisense inhibition and chemotherapeutic combination treatments for the proliferation of endometrial cancer in vitro and in vivo].
Chen XJ; Zheng W; Chen LL; Chen ZB; Wang SQ
Zhonghua Yi Xue Za Zhi; 2004 Oct; 84(20):1721-5. PubMed ID: 15569435
[TBL] [Abstract][Full Text] [Related]
28. [Effects of cis-platinum diammine dichloride on yolk sac tumor transplanted in nude mice (author's transl)].
Sawada M; Matsui Y; Nishiura H; Yagyu M; Hayakawa K; Okudaira Y; Kawashima M; Iwanaga K
Acta Obstet Gynaecol Jpn; 1981 Apr; 33(4):519-24. PubMed ID: 7195137
[TBL] [Abstract][Full Text] [Related]
29. Interstitial wires releasing diffusing alpha emitters combined with chemotherapy improved local tumor control and survival in squamous cell carcinoma-bearing mice.
Cooks T; Arazi L; Efrati M; Schmidt M; Marshak G; Kelson I; Keisari Y
Cancer; 2009 Apr; 115(8):1791-801. PubMed ID: 19197995
[TBL] [Abstract][Full Text] [Related]
30. Methionine starvation modulates the efficacy of cisplatin on human breast cancer in nude mice.
Hoshiya Y; Kubota T; Matsuzaki SW; Kitajima M; Hoffman RM
Anticancer Res; 1996; 16(6B):3515-7. PubMed ID: 9042214
[TBL] [Abstract][Full Text] [Related]
31. A synthetic retinoid, TAC-101 (4-[3,5-bis (trimethylsilyl) benzamido] benzoic acid), plus cisplatin: potential new therapy for ovarian clear cell adenocarcinoma.
Ezawa S; Suzuki N; Ohie S; Higashiguchi A; Hosoi F; Kitazato K; Susumu N; Aoki D
Gynecol Oncol; 2008 Mar; 108(3):627-31. PubMed ID: 18048092
[TBL] [Abstract][Full Text] [Related]
32. [Antitumor effects of high-dose cisplatin in hypertonic saline against human ovarian tumors heterotransplanted in nude mice].
Sawada M; Ozaki M; Hongo J; Hirota Y; Inagaki M; Koizumi K; Okamoto E
Nihon Sanka Fujinka Gakkai Zasshi; 1987 Jul; 39(7):1103-7. PubMed ID: 3611881
[TBL] [Abstract][Full Text] [Related]
33. Use of nude mouse xenografts as preclinical drug screens: in vivo activity of established chemotherapeutic agents against melanoma and ovarian carcinoma xenografts.
Taetle R; Rosen F; Abramson I; Venditti J; Howell S
Cancer Treat Rep; 1987 Mar; 71(3):297-304. PubMed ID: 3815395
[TBL] [Abstract][Full Text] [Related]
34. Sensitization of tumor-associated endothelial cell apoptosis by the novel vascular-targeting agent ZD6126 in combination with cisplatin.
Goto H; Yano S; Matsumori Y; Ogawa H; Blakey DC; Sone S
Clin Cancer Res; 2004 Nov; 10(22):7671-6. PubMed ID: 15570000
[TBL] [Abstract][Full Text] [Related]
35. Chemotherapy of human yolk sac tumor heterotransplanted in nude mice.
Sawada M; Matsui Y; Okudaira Y
J Natl Cancer Inst; 1983 Dec; 71(6):1221-5. PubMed ID: 6197552
[TBL] [Abstract][Full Text] [Related]
36. Recombinant CD40 ligand therapy has significant antitumor effects on CD40-positive ovarian tumor xenografts grown in SCID mice and demonstrates an augmented effect with cisplatin.
Ghamande S; Hylander BL; Oflazoglu E; Lele S; Fanslow W; Repasky EA
Cancer Res; 2001 Oct; 61(20):7556-62. PubMed ID: 11606394
[TBL] [Abstract][Full Text] [Related]
37. Rapid development of drug resistance in human ovarian tumor xenografts after a single treatment with melphalan in Vivo.
Caffrey PB; Zhang Y; Frenkel GD
Anticancer Res; 1998; 18(4C):3021-5. PubMed ID: 9713503
[TBL] [Abstract][Full Text] [Related]
38. Enhancement of cisplatin sensitivity of quiescent cells in solid tumors by combined treatment with tirapazamine and low-temperature hyperthermia.
Masunaga S; Ono K; Hori H; Akaboshi M; Kawai K; Suzuki M; Kinashi Y; Kasai S; Nagasawa H; Uto Y
Radiat Med; 1998; 16(6):441-8. PubMed ID: 9929144
[TBL] [Abstract][Full Text] [Related]
39. Time dependence of the selective modulation of cisplatin-induced nephrotoxicity by WR2721 in the mouse.
Treskes M; Boven E; Holwerda U; Pinedo HM; van der Vijgh WJ
Cancer Res; 1992 Apr; 52(8):2257-60. PubMed ID: 1313740
[TBL] [Abstract][Full Text] [Related]
40. Adjuvant effects of calmodulin antagonists on antitumor activity of 1-(2-tetrahydrofuryl)-5-fluorouracil (ftorafur) and a mixture of ftorafur and uracil (UFT) in nude mice bearing human ovarian carcinomas.
Kikuchi Y; Oomori K; Iwano I; Kizawa I; Miyauchi M; Kita T; Kuki E
Gynecol Oncol; 1989 Nov; 35(2):172-6. PubMed ID: 2509301
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
